Evidence map›Paper›PMID 30561541›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019

Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.

Sarah B Joseph, Laura P Kincer, Natalie M Bowman, Chris Evans, Michael J Vinikoor, Christopher K Lippincott, Magnus Gisslén, Serena Spudich, Prema Menezes, Kevin Robertson and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 82 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. ΔJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Sarah B JosephDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Maryland.
Laura P KincerDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Maryland.
Natalie M BowmanDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Maryland.
Chris EvansDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Maryland.
Michael J VinikoorDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Maryland.
Christopher K LippincottDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Magnus GisslénDepartment of Infectious Diseases, Sahlgrenska Academy at the University of Gothenburg, Sweden.
Serena SpudichDepartment of Neurology, Yale University School of Medicine, New Haven, Connecticut.
Prema MenezesDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Maryland.
Kevin RobertsonDepartment of Neurology, University of North Carolina at Chapel Hill, San Francisco.
Nancie ArchinDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Maryland.
Angela KashubaUniversity of North Carolina Center for AIDS Research, University of North Carolina at Chapel Hill, San Francisco.
Joseph J EronDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Maryland.
Richard W PriceDepartment of Neurology, University of California, San Francisco.
Ronald SwanstromUniversity of North Carolina Center for AIDS Research, University of North Carolina at Chapel Hill, San Francisco.
University of North Carolina at Chapel Hill · USJohns Hopkins University · USUniversity of California, San Francisco · USUniversity of Gothenburg · SEYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Persistent CSF HIV despite successful cART: Viral Tropism, Drug Penetration andP01MH094177 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SWANSTROM, RONALD I · 2011 to 2015
$4.5M
Compartmentalized CSF viral escape and the CNS HIV reservoirR01NS094067 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRICE, RICHARD W. · 2015 to 2020
$3.9M
NCATS NIH HHS UL1 TR001863NIAID NIH HHS P30 AI050410NIMH NIH HHS P01 MH094177NINDS NIH HHS R01 NS094067
6 · The paper itself

Abstract

backgroundHuman immunodeficiency virus type 1 (HIV-1) populations are detected in cerebrospinal fluid (CSF) of some people on suppressive antiretroviral therapy (ART). Detailed analysis of these populations may reveal whether they are produced by central nervous system (CNS) reservoirs.

methodsWe performed a study of 101 asymptomatic participants on stable ART. HIV-1 RNA concentrations were cross-sectionally measured in CSF and plasma. In participants with CSF HIV-1 RNA concentrations sufficient for analysis, viral populations were genetically and phenotypically characterized over multiple time points.

resultsFor 6% of participants (6 of 101), the concentration of HIV-1 RNA in their CSF was ≥0.5 log copies/mL above that of plasma (ie, CSF escape). We generated viral envelope sequences from CSF of 3 participants. One had a persistent CSF escape population that was macrophage-tropic, partially drug resistant, genetically diverse, and closely related to a minor macrophage-tropic lineage present in the blood prior to viral suppression and enriched for after ART. Two participants (1 suppressed and 1 not) had transient CSF escape populations that were R5 T cell-tropic with little genetic diversity.

conclusionsExtensive analysis of viral populations in 1 participant revealed that CSF escape was from a persistently replicating population, likely in macrophages/microglia, present in the CNS over 3 years of ART. CSF escape in 2 other participants was likely produced by trafficking and transient expansion of infected T cells in the CNS. Our results show that CNS reservoirs can persist during ART and that CSF escape is not exclusively produced by replicating CNS reservoirs.

Indexed as

AdultAnti-Retroviral AgentsAsymptomatic DiseasesCentral Nervous SystemCerebrospinal FluidCohort StudiesCross-Sectional StudiesDrug Resistance, ViralFemaleHIV-1HIV InfectionsHumansLongitudinal StudiesMaleMiddle AgedPlasmaAnti-Retroviral AgentsRNA, ViralCNSCSF escapedrug resistanceHIV reservoirspersistence

Identifiers

PMID30561541
PMCPMC6938202
OpenAlexW2903834810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.